A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)

This study is testing BEY1107 combined with temozolomide (standard chemotherapy) in patients with glioblastoma (GBM) — a severe brain cancer — that has come back or is growing again after initial treatment. **You may be eligible if...** - You are 19 years old or older - You have confirmed glioblastoma that has progressed or returned after standard first-line treatment - You have at least one measurable or evaluable tumor on brain imaging - You are in good overall health (ECOG 0–1) - If on steroids, your dose is stable **You may NOT be eligible if...** - Your glioblastoma is newly diagnosed (not yet treated) - You are in poor health or have organ dysfunction - You have certain medical conditions that interfere with the study drugs Talk to your doctor to see if this trial is right for you.